MYC RNAi-PT Combination Nanotherapy for Metastatic Prostate Cancer Treatment

Abstract

The main objective of this project is to develop an innovative nanotherapy modality by combining platinum (Pt) chemotherapy and MYC-targeting RNA interference (RNAi) for more effective treatment of metastatic prostate cancer (PCa). Two specific aims are proposed in this study, including (i) development and optimization of MYC siRNA-Pt nanoparticles (NPs), and (2) determination of the efficacy of select NPs in the B13MYC/Cre|Ptenfl/fl engineered PCa mouse model. This project is directed by an interdisciplinary team in the PCa research field, including Initiating PI Dr. Omid Farokhzad from Brigham and Womens Hospital (BWH)/Harvard Medical School (HMS), Partnering PIs Dr. Charles Bieberich from the University of Maryland Baltimore County (UMBC) and Dr. Angelo De Marzo from the John Hopkins University (JHU), and two co-investigators (Dr. Srinivasan Yegnasubramanian from JHU and Dr. Jinjun Shi from BWH/HMS).

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2017
Accession Number
AD1050801

Entities

People

  • Angelo Demarzo

Organizations

  • Johns Hopkins University

Tags

DTIC Thesaurus Topics

  • Biological Sciences
  • Biomedical Research
  • Cell Line
  • Diseases And Disorders
  • Genetics
  • Health Services
  • Hospitals
  • Maryland
  • Medical Personnel
  • Nanoparticles
  • Nanotherapy
  • Neoplasms
  • Prostate
  • Prostate Cancer
  • Schools
  • Students
  • Tissues

Readers

  • Aerial Delivery - Logistics and Supply Chain Management.
  • Oncology (Cancer Research).
  • Prostate Cancer Biology.

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech